Ophthotech Corp. Company Profile (NASDAQ:OPHT)

About Ophthotech Corp.

Ophthotech Corp. logoOphthotech Corporation is a biopharmaceutical company. The Company specializes in the development of therapeutics to treat diseases of the back of the eye, with a focus on developing therapeutics for age-related macular degeneration (AMD). Its advanced product candidate is Fovista, which is for use in combination with anti-vascular endothelial growth factor (VEGF) drugs. It is also developing its product candidate Zimura for the treatment of patients with geographic atrophy, a form of dry AMD, in combination with VEGF therapy for the treatment of polypoidal choroidal vasculopathy (PCV). Fovista is being tested in Phase III clinical development. In addition, it has initiated additional clinical trials to evaluate the potential additional benefits of Fovista administered in combination with anti-VEGF drugs in wet AMD patients, known as Fovista Expansion Studies. Zimura has completed a small, multicenter, uncontrolled, open label Phase I/IIa clinical trial.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: OPHT
  • CUSIP:
Key Metrics:
  • Previous Close: $36.12
  • 50 Day Moving Average: $49.30
  • 200 Day Moving Average: $51.87
  • 52-Week Range: $35.80 - $80.00
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -7.78
  • P/E Growth: 0.00
  • Market Cap: $1.29B
  • Outstanding Shares: 35,593,000
  • Beta: 2.14
  • Net Margins: -271.28%
  • Return on Equity: -296.63%
  • Return on Assets: -34.00%
  • Current Ratio: 8.95%
  • Quick Ratio: 8.95%
Additional Links:
Companies Related to Ophthotech Corp.:

Analyst Ratings

Consensus Ratings for Ophthotech Corp. (NASDAQ:OPHT) (?)
Ratings Breakdown: 1 Sell Rating, 9 Buy Ratings
Consensus Rating:Buy (Score: 2.80)
Consensus Price Target: $86.10 (138.37% upside)

Analysts' Ratings History for Ophthotech Corp. (NASDAQ:OPHT)
DateFirmActionRatingPrice TargetDetails
10/3/2016BTIG ResearchReiterated RatingBuy$92.00View Rating Details
10/1/2016Cowen and CompanySet Price TargetBuy$60.00View Rating Details
9/30/2016Leerink SwannReiterated RatingPositive$72.00View Rating Details
9/8/2016JPMorgan Chase & Co.Boost Price TargetOverweight$81.00 -> $95.00View Rating Details
8/10/2016Goldman Sachs Group Inc.Reiterated RatingSell$45.00View Rating Details
8/4/2016Citigroup Inc.Boost Price TargetBuy$91.00 -> $92.00View Rating Details
7/19/2016Barclays PLCReiterated RatingBuyView Rating Details
1/27/2016Chardan CapitalReiterated RatingBuyView Rating Details
1/6/2016SunTrust Banks Inc.Initiated CoverageBuy$100.00View Rating Details
11/19/2015Oppenheimer Holdings Inc.Reiterated RatingOutperform$95.00View Rating Details
8/6/2015Stifel NicolausReiterated RatingBuy$74.00 -> $83.00View Rating Details
(Data available from 10/23/2014 forward)


Earnings History for Ophthotech Corp. (NASDAQ:OPHT)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/3/2016Q216($1.05)($0.85)$18.64 million$28.20 millionViewListenView Earnings Details
5/4/2016Q116($1.33)($1.03)$7.22 million$15.70 millionViewListenView Earnings Details
2/24/2016Q415($1.35)($1.02)$7.59 million$4.78 millionViewListenView Earnings Details
11/5/2015Q315($0.98)($1.14)$11.31 million$3.40 millionViewN/AView Earnings Details
8/5/2015Q215($1.02)($1.08)$2.77 million$1.60 millionViewN/AView Earnings Details
5/11/2015Q115($0.75)$0.22$3.68 million$41.70 millionViewListenView Earnings Details
2/23/2015Q414($0.57)($1.06)$12.36 million$1.68 millionViewN/AView Earnings Details
11/11/2014Q314($0.62)$0.31$8.02 million$39.58 millionViewN/AView Earnings Details
8/6/2014Q214($0.56)($1.57)$4.31 millionViewN/AView Earnings Details
5/13/2014Q1($0.67)($0.64)ViewListenView Earnings Details
2/27/2014($0.50)($0.65)ViewN/AView Earnings Details
11/13/2013Q313($1.00)($10.26)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Ophthotech Corp. (NASDAQ:OPHT)
Current Year EPS Consensus Estimate: $-4.96 EPS
Next Year EPS Consensus Estimate: $-4.64 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20164($1.50)($1.35)($1.43)
Q2 20163($1.24)($0.66)($0.89)
Q3 20162($1.62)($1.58)($1.60)
Q4 20162($1.78)($0.51)($1.15)
(Data provided by Zacks Investment Research)


Dividend History for Ophthotech Corp. (NASDAQ:OPHT)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Ophthotech Corp. (NASDAQ:OPHT)
Insider Ownership Percentage: 2.00%
Institutional Ownership Percentage: 93.48%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/3/2016David R GuyerCEOSell22,060$44.37$978,802.20View SEC Filing  
9/29/2016Samir Chandrakant PatelPresidentSell20,000$55.17$1,103,400.00View SEC Filing  
8/29/2016Samir Chandrakant PatelPresidentSell20,000$52.80$1,056,000.00View SEC Filing  
8/1/2016David R GuyerCEOSell24,060$64.47$1,551,148.20View SEC Filing  
7/29/2016Samir Chandrakant PatelPresidentSell20,000$64.21$1,284,200.00View SEC Filing  
7/1/2016David R GuyerCEOSell24,060$52.12$1,254,007.20View SEC Filing  
6/30/2016Samir Chandrakant PatelPresidentSell41,846$51.23$2,143,770.58View SEC Filing  
6/3/2016Axel BolteDirectorBuy3,500$56.97$199,395.00View SEC Filing  
6/2/2016Glenn SblendorioCFOSell671$57.20$38,381.20View SEC Filing  
6/1/2016David R GuyerCEOSell30,060$52.71$1,584,462.60View SEC Filing  
5/31/2016Samir Chandrakant PatelPresidentSell20,000$53.32$1,066,400.00View SEC Filing  
5/24/2016A/S NovoMajor ShareholderSell1,300,000$49.00$63,700,000.00View SEC Filing  
5/2/2016David R GuyerCEOSell22,060$46.18$1,018,730.80View SEC Filing  
4/29/2016Samir Chandrakant PatelPresidentSell20,000$46.79$935,800.00View SEC Filing  
4/1/2016David R GuyerCEOSell22,060$44.11$973,066.60View SEC Filing  
3/29/2016Samir Chandrakant PatelPresidentSell20,000$41.85$837,000.00View SEC Filing  
3/1/2016David R GuyerCEOSell22,060$45.48$1,003,288.80View SEC Filing  
2/29/2016Samir Chandrakant PatelPresidentSell20,000$45.13$902,600.00View SEC Filing  
1/29/2016Samir Chandrakant PatelPresidentSell20,000$53.59$1,071,800.00View SEC Filing  
1/28/2016David R. GuyerCEOSell18,598$53.63$997,410.74View SEC Filing  
1/11/2016Nicholas GalakatosDirectorSell3,000$65.72$197,160.00View SEC Filing  
1/4/2016Barbara A. WoodSVPSell1,000$76.37$76,370.00View SEC Filing  
12/30/2015David R. GuyerCEOSell18,582$78.82$1,464,633.24View SEC Filing  
12/30/2015Glenn SblendorioDirectorSell2,000$80.00$160,000.00View SEC Filing  
12/29/2015Samir Chandrakant PatelPresidentSell1,184$77.50$91,760.00View SEC Filing  
12/24/2015Samir Chandrakant PatelPresidentSell26,036$77.09$2,007,115.24View SEC Filing  
12/10/2015Nicholas GalakatosDirectorSell3,000$64.44$193,320.00View SEC Filing  
12/1/2015Barbara A. WoodSVPSell2,000$63.24$126,480.00View SEC Filing  
11/30/2015David R. GuyerCEOSell18,582$62.49$1,161,189.18View SEC Filing  
11/24/2015Samir Chandrakant PatelPresidentSell27,215$60.27$1,640,248.05View SEC Filing  
11/18/2015Nicholas GalakatosDirectorSell1,500$60.00$90,000.00View SEC Filing  
11/5/2015Samir Chandrakant PatelPresidentSell20,687$53.55$1,107,788.85View SEC Filing  
10/21/2015Samir Chandrakant PatelPresidentSell27,215$43.27$1,177,593.05View SEC Filing  
10/16/2015Barbara A. WoodSVPSell2,000$45.00$90,000.00View SEC Filing  
9/29/2015David R. GuyerCEOSell18,582$37.69$700,355.58View SEC Filing  
9/21/2015Samir Chandrakant PatelPresidentSell27,215$46.34$1,261,143.10View SEC Filing  
8/31/2015David R. GuyerCEOSell18,582$44.88$833,960.16View SEC Filing  
8/20/2015Samir Chandrakant PatelPresidentSell27,215$48.75$1,326,731.25View SEC Filing  
7/20/2015Samir Chandrakant PatelPresidentSell27,215$67.87$1,847,082.05View SEC Filing  
7/17/2015Glenn SblendorioDirectorSell3,000$67.33$201,990.00View SEC Filing  
7/1/2015Barbara A WoodSVPSell2,000$51.94$103,880.00View SEC Filing  
6/29/2015David R GuyerCEOSell18,582$51.05$948,611.10View SEC Filing  
6/18/2015Samir Chandrakant PatelPresidentSell12,000$49.78$597,360.00View SEC Filing  
5/28/2015David R GuyerCEOSell18,582$48.62$903,456.84View SEC Filing  
4/29/2015David R GuyerCEOSell18,582$48.45$900,297.90View SEC Filing  
4/17/2015Samir Chandrakant PatelPresidentSell12,000$50.47$605,640.00View SEC Filing  
3/30/2015Axel BolteDirectorBuy500$48.27$24,135.00View SEC Filing  
3/30/2015David R GuyerCEOSell18,582$48.26$896,767.32View SEC Filing  
3/2/2015Barbara A WoodSVPSell2,000$53.26$106,520.00View SEC Filing  
3/2/2015David R GuyerCEOSell18,582$53.22$988,934.04View SEC Filing  
1/2/2015David R GuyerCEOSell15,034$45.34$681,641.56View SEC Filing  
11/13/2014A/S NovoMajor ShareholderSell995,000$40.20$39,999,000.00View SEC Filing  
11/3/2014David R GuyerCEOSell15,034$39.71$597,000.14View SEC Filing  
10/2/2014David R GuyerCEOSell2,807$38.52$108,125.64View SEC Filing  
10/2/2014Samir Chandrakant PatelPresidentSell1,965$38.04$74,748.60View SEC Filing  
10/1/2014David R GuyerCEOSell12,227$37.30$456,067.10View SEC Filing  
10/1/2014Samir Chandrakant PatelPresidentSell17,676$37.28$658,961.28View SEC Filing  
9/4/2014David R GuyerCEOSell1,107$38.58$42,708.06View SEC Filing  
8/1/2014Bruce PeacockCFOSell6,191$37.78$233,895.98View SEC Filing  
8/1/2014David R GuyerCEOSell13,136$37.85$497,197.60View SEC Filing  
8/1/2014Samir Chandrakant PatelPresidentSell18,986$37.80$717,670.80View SEC Filing  
7/1/2014Bruce PeacockCFOSell7,739$41.07$317,840.73View SEC Filing  
7/1/2014David R GuyerCEOSell15,034$41.08$617,596.72View SEC Filing  
7/1/2014Samir Chandrakant PatelPresidentSell18,986$41.08$779,944.88View SEC Filing  
6/16/2014Nicholas GalakatosDirectorSell144,976$44.17$6,403,589.92View SEC Filing  
6/11/2014Lifesciences Ii L.P. ClarusMajor ShareholderSell211,680$45.42$9,614,505.60View SEC Filing  
6/4/2014Svlsf Iv, LlcMajor ShareholderSell1,966,935$42.54$83,673,414.90View SEC Filing  
6/3/2014Bruce PeacockCFOSell13,931$40.12$558,911.72View SEC Filing  
6/3/2014Svlsf Iv, LlcMajor ShareholderSell1,865,619$40.65$75,837,412.35View SEC Filing  
6/2/2014David R GuyerCEOSell25,417$39.92$1,014,646.64View SEC Filing  
6/2/2014Samir Chandrakant PatelPresidentSell27,873$39.91$1,112,411.43View SEC Filing  
5/30/2014Svlsf Iv, LlcMajor ShareholderSell931,869$40.99$38,197,310.31View SEC Filing  
5/28/2014Svlsf Iv, LlcMajor ShareholderSell980,127$40.19$39,391,304.13View SEC Filing  
5/23/2014Svlsf Iv, LlcMajor ShareholderSell330,450$38.10$12,590,145.00View SEC Filing  
5/13/2014Hbm Healthcare Investments (Camajor shareholderSell500,000$29.75$14,875,000.00View SEC Filing  
5/1/2014Bruce PeacockCFOSell4,643$32.43$150,572.49View SEC Filing  
5/1/2014David GuyerCEOSell10,665$33.71$359,517.15View SEC Filing  
5/1/2014Samir Chandrakant PatelPresidentSell14,319$32.45$464,651.55View SEC Filing  
3/24/2014Bruce PeacockCFOSell6,137$34.77$213,383.49View SEC Filing  
3/24/2014David GuyerCEOSell12,027$34.53$415,292.31View SEC Filing  
3/24/2014Samir Chandrakant PatelPresidentSell16,876$34.54$582,897.04View SEC Filing  
2/18/2014Svlsf Iv, Llcmajor shareholderSell2,111,364$29.61$62,517,488.04View SEC Filing  
9/30/2013A/S NovoInsiderBuy455,000$22.00$10,010,000.00View SEC Filing  
9/30/2013Hbm Healthcare Investments (CaMajor ShareholderBuy228,000$22.00$5,016,000.00View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Ophthotech Corp. (NASDAQ:OPHT)
News IconNoteworthy Analyst Ratings of Two Stocks Ophthotech Corp ... - The Voice Registrar (NASDAQ:OPHT)
voiceregistrar.com - October 22 at 6:08 PM
News IconRunning out of Gas? Stock Touching New Recent Low: Ophthotech Corporation (NASDAQ:OPHT) - CSZ News (NASDAQ:OPHT)
cincysportszone.com - October 20 at 12:27 PM
capitalcube.com logoETF’s with exposure to Ophthotech Corp. : October 19, 2016 (NASDAQ:OPHT)
www.capitalcube.com - October 19 at 6:58 PM
News IconBNP Paribas Arbitrage SA invests in Ophthotech Corp. (OPHT ... - DailyQuint (NASDAQ:OPHT)
dailyquint.com - October 15 at 11:20 AM
News IconAnalyst Coverage: Ophthotech Corporation (NASDAQ:OPHT ... - NewsDen (NASDAQ:OPHT)
newsden.net - October 14 at 9:52 AM
seekingalpha.com logoRevisiting The Investment Case On Ophthotech (NASDAQ:OPHT)
seekingalpha.com - October 12 at 6:33 PM
News IconResearch Analysts' Recent Ratings Changes for Ophthotech Corp ... - DailyQuint (NASDAQ:OPHT)
dailyquint.com - October 12 at 12:00 PM
News Icon2 Biotech Stocks News And Price Trends: Ophthotech Corporation (NASDAQ:OPHT), Alnylam Pharmaceuticals, Inc ... - The Voice Registrar (NASDAQ:OPHT)
voiceregistrar.com - October 11 at 6:54 PM
News IconTrading the Biotech News: Northwest Biotherapeutics, Inc. (NASDAQ:NWBO), Ophthotech Corporation (NASDAQ:OPHT) - The Voice Registrar (NASDAQ:OPHT)
voiceregistrar.com - October 10 at 11:22 AM
seekingalpha.com logoRevisiting The Investment Case On Ophthotech - Seeking Alpha (NASDAQ:OPHT)
seekingalpha.com - October 10 at 11:22 AM
fool.com logoHere's Why Ophtotech Corporation Dropped 16.5% in September (NASDAQ:OPHT)
www.fool.com - October 8 at 11:02 AM
insidermonkey.com logoHere’s Why Investors Are Buzzing About NXP Semiconductors, Ophthotech, Trina Solar, and Two Other Stocks (NASDAQ:OPHT)
www.insidermonkey.com - October 6 at 6:25 PM
investors.com logoOphthotech's Eye Disease Med Could Beat Down Rival Regeneron (NASDAQ:OPHT)
www.investors.com - October 6 at 6:25 PM
News IconTime To Put On The Watch List? - Ophthotech Corporation (NASDAQ:OPHT), Neuralstem, Inc. (NASDAQ:CUR) - The Voice Registrar (NASDAQ:OPHT)
voiceregistrar.com - October 6 at 12:05 PM
finance.yahoo.com logoTheravance (TBPH) Starts Dosing in Ulcerative Colitis Study (NASDAQ:OPHT)
finance.yahoo.com - October 5 at 11:51 AM
finance.yahoo.com logoRoche (RHHBY) Actemra Gets Breakthrough Therapy Status (NASDAQ:OPHT)
finance.yahoo.com - October 5 at 11:51 AM
thecountrycaller.com logoOphthotech Corp (OPHT): Analyst Sees Over 111% Upside Amid Failed Regeneron Study (NASDAQ:OPHT)
www.thecountrycaller.com - October 4 at 6:12 PM
seekingalpha.com logoOphthotech: A Buying Opportunity? (NASDAQ:OPHT)
seekingalpha.com - October 4 at 6:12 PM
News IconStock within Traders Limelight: Ophthotech Corporation (NASDAQ:OPHT) (NASDAQ:OPHT)
crcconnection.com - October 4 at 6:12 PM
thecountrycaller.com logoOphthotech Corp (OPHT): Analyst Sees Over 111% Upside Amid Failed Regeneron Study - TCC (NASDAQ:OPHT)
www.thecountrycaller.com - October 4 at 11:22 AM
benzinga.com logoHard To See If Regeneron's Eylea Combo Study Failure Reads Through To Ophthotech's Fovista - Benzinga (NASDAQ:OPHT)
www.benzinga.com - October 3 at 6:11 PM
seekingalpha.com logoOphthotech: A Buying Opportunity? - Seeking Alpha (NASDAQ:OPHT)
seekingalpha.com - October 3 at 6:11 PM
News IconReuters Health News Summary - Daily Mail (NASDAQ:OPHT)
www.dailymail.co.uk - October 1 at 5:51 PM
benzinga.com logoHere's Why Ophthotech Is Trading Down On Regeneron's News (NASDAQ:OPHT)
www.benzinga.com - October 1 at 11:54 AM
benzinga.com logoVectrus Inc (NYSE:VEC), Threshold Pharmaceuticals, Inc. (NASDAQ ... - Benzinga (NASDAQ:OPHT)
www.benzinga.com - September 30 at 6:43 PM
News IconIntraday Active Biotech Stocks News: Galena Biopharma, Inc ... - The Voice Registrar (NASDAQ:OPHT)
voiceregistrar.com - September 30 at 6:43 PM
fool.com logoHere's Why Ophthotech Corporation Is Dropping Today - Motley Fool (NASDAQ:OPHT)
www.fool.com - September 30 at 6:43 PM
fool.com logoHere's Why Ophthotech Corporation Is Dropping Today (NASDAQ:OPHT)
www.fool.com - September 30 at 12:40 PM
benzinga.com logoHere's Why Ophthotech Is Trading Down On Regeneron's News - Benzinga (NASDAQ:OPHT)
www.benzinga.com - September 30 at 11:51 AM
investors.com logoRegeneron Pharmaceuticals Falls As Combo Therapy Worse Than Eylea Alone (NASDAQ:OPHT)
www.investors.com - September 30 at 11:51 AM
News IconCurrent Price Targets For Ophthotech Corporation (NASDAQ:OPHT) - NewsDen (NASDAQ:OPHT)
newsden.net - September 29 at 6:33 PM
News IconOphthotech Corporation (NASDAQ:OPHT) Updated Broker Price Targets - The De Soto Edge (NASDAQ:OPHT)
desotoedge.com - September 29 at 6:33 PM
capitalcube.com logoETF’s with exposure to Ophthotech Corp. : September 26, 2016 (NASDAQ:OPHT)
www.capitalcube.com - September 26 at 11:22 AM
News IconSell-side is Weighing in on Ophthotech Corporation (NASDAQ ... - Frisco Fastball (NASDAQ:OPHT)
friscofastball.com - September 23 at 11:19 AM
News IconOphthotech Corp. (NASDAQ: OPHT) Rating Reiterated at BTIG Research - The Woodbridge Citizen (NASDAQ:OPHT)
www.woodbridgecitizen.com - September 23 at 11:19 AM
News IconBiotech Stocks Worth a Closer Look: Aduro BioTech, Inc. (NASDAQ ... - The Voice Registrar (NASDAQ:OPHT)
voiceregistrar.com - September 20 at 11:54 AM
capitalcube.com logoOphthotech Corp. – Value Analysis (NASDAQ:OPHT) : September 19, 2016 (NASDAQ:OPHT)
www.capitalcube.com - September 19 at 6:36 PM
capitalcube.com logoOphthotech Corp. breached its 50 day moving average in a Bullish Manner : OPHT-US : September 16, 2016 (NASDAQ:OPHT)
www.capitalcube.com - September 16 at 10:07 AM
finance.yahoo.com logoBiotech bright spots (NASDAQ:OPHT)
finance.yahoo.com - September 15 at 6:41 PM
kcregister.com logoDon't Miss: Ophthotech Corporation (NASDAQ:OPHT), Aeterna ... - KC Register (NASDAQ:OPHT)
www.kcregister.com - September 12 at 6:18 PM
streetinsider.com logoForm 4 Ophthotech Corp. For: Sep 01 Filed by: GUYER DAVID R (NASDAQ:OPHT)
www.streetinsider.com - September 7 at 6:46 PM
nasdaq.com logoOphthotech Breaks Above 200-Day Moving Average - Bullish for OPHT (NASDAQ:OPHT)
www.nasdaq.com - September 7 at 6:46 PM
seekingalpha.com logoMidatech Is Something To Keep An Eye On (NASDAQ:OPHT)
seekingalpha.com - September 6 at 6:45 PM
finance.yahoo.com logoOphthotech Corporation to Present at the Morgan Stanley Global Healthcare Conference (NASDAQ:OPHT)
finance.yahoo.com - September 6 at 11:21 AM
News IconOphthotech Corp (NASDAQ:OPHT) Analyst Estimates | The ... - The Independent Republic (NASDAQ:OPHT)
theindependentrepublic.com - August 23 at 6:49 PM
capitalcube.com logoETF’s with exposure to Ophthotech Corp. : August 23, 2016 (NASDAQ:OPHT)
www.capitalcube.com - August 23 at 6:48 PM
nasdaq.com logoOphthotech is Now Oversold (OPHT) (NASDAQ:OPHT)
www.nasdaq.com - August 19 at 6:34 PM
finance.yahoo.com logoOphthotech's Fovista Has Potential To Break Through The 'Therapeutic Ceiling' Of Anti-VEGF Therapies (NASDAQ:OPHT)
finance.yahoo.com - August 19 at 6:34 PM
fidaily.com logoBTIG Research Starts Coverage on Ophthotech Corporation (OPHT) Setting A Rating Of “Buy” (NASDAQ:OPHT)
www.fidaily.com - August 19 at 9:42 AM
News IconReal-World Anti-VEGF Data Disappointing (NASDAQ:OPHT)
www.medscape.com - August 11 at 7:07 PM


Ophthotech Corp. (NASDAQ:OPHT) Chart for Sunday, October, 23, 2016

Last Updated on 10/23/2016 by MarketBeat.com Staff